(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 August 2025 (14.08.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/170868 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61K 31/713* (2006.01)
A61K 31/7115 (2006.01) *A61P 3/06* (2006.01)
A61K 31/712 (2006.01) *A61P 9/00* (2006.01)

(21) International Application Number:
PCT/US2025/014357

(22) International Filing Date:
03 February 2025 (03.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/549,870 05 February 2024 (05.02.2024) US
63/703,100 03 October 2024 (03.10.2024) US

(71) Applicant: **SIRIUS THERAPEUTICS, INC.** [US/US]; 11760 Sorrento Valley Road, San Diego, California 92121 (US).

(72) Inventors: **BRADSHAW, Curt W.**; 11760 Sorrento Valley Road, San Diego, California 92121 (US). **NICHOLAS, Anthony**; 11760 Sorrento Valley Road, San Diego, California 92121 (US).

(74) Agent: **SHIN, Minyoung** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

WO 2025/170868 A1

(54) Title: POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A) OR APOC3, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF



FIG. 2

(57) Abstract: Disclosed herein are polynucleic acid molecules that can be utilized for suppressing the expression of lipoprotein(a) (Lp(a)) gene or apolipoprotein C3 (APOC3). Also, described herein are pharmaceutical compositions comprising polynucleic acid molecules targeting lipoprotein(a) (Lp(a)) gene or apolipoprotein C3 (APOC3) mRNA. Further provided herein are methods for suppressing the expression of lipoprotein(a) (Lp(a)) gene or apolipoprotein C3 (APOC3) by utilizing the polynucleic acid molecules described herein.

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*